Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and in vitro mechanisms with no new human data
PubMed 38102454 · doi:10.1038/s43587-023-00539-2
What was done
The authors conducted a narrative review of epigenetic rejuvenation strategies using partial nuclear reprogramming in mouse and human model systems. They evaluated individual classical reprogramming factors, novel factors, chemical approaches, chromatin remodeling dynamics, and potential strategies to address practical challenges in treating age-related diseases.
What was found
The abstract reports no numerical findings or quantitative effect sizes. It qualitatively describes that transient systemic or tissue-specific expression of reprogramming factors combats age-related deterioration at cellular, tissue, and organismal levels in mouse and human experimental models.
Why it matters
This review outlines the mechanistic landscape and translational challenges for partial reprogramming, a major prospective strategy to reverse cellular aging markers without complete pluripotency induction.
Limits
The abstract describes preclinical rodent and cellular models without clinical trials or in vivo human efficacy data. No specific numbers of cited studies, quantitative metrics, or detailed toxicity profiles are reported in the abstract.
Cited by
- context Oral administration of a liquid chemical compound can rejuvenate mouse tissues, such as skin and ears, within four weeks.
- context David Sinclair's group has successfully performed age reversal interventions in non-human primates (monkeys).